Literature DB >> 34453586

Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer.

Qingqing Lin1, Wenchao Liu2, Song Xu3, Liping Sun4.   

Abstract

BACKGROUND: The effect of serum lipids on ovarian cancer is controversial. We conducted this study to evaluate the prognostic value of preoperative plasma lipid profile in patients with ovarian cancer.
METHODS: The medical records of 156 epithelial ovarian cancer patients who underwent surgical resection in our department were retrospectively reviewed and analyzed. Serum lipids profiles, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), apolipoprotein A-I (apoA-I), apolipoprotein B (apoB) and clinicopathologic data, were analyzed. Cox proportional hazards regression analyses and Kaplan-Meier method were performed to evaluate the overall survival (OS) and progression-free survival (PFS).
RESULTS: Multivariable Cox regression analysis found that preoperative higher LDL-C level was significantly associated with worse OS (HR 2.088, 95% CI 1.052-4.147, p = 0.035), whereas higher HDL-C level showed significant association with better PFS (HR 0.491, 95% CI 0.247-0.975, p = 0.042). Further Kaplan-Meier survival analysis demonstrated that OS was longer for patients with low levels of LDL-C (< 2.76 mmol/L) compared to those with high levels of LDL-C (≥ 2.76 mmol/L) (P = 0.028), and PFS was better for patients with high levels of HDL-C (≥ 1.19 mmol/L) compared to those with low levels of HDL-C (< 1.19 mmol/L) (P = 0.001).
CONCLUSIONS: Preoperative HDL-C and LDL-C levels are significant predictors of clinical outcome in patients with epithelial ovarian cancer.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  High-density lipoprotein cholesterol; Low-density lipoprotein cholesterol; Ovarian cancer; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 34453586     DOI: 10.1007/s00404-021-06215-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  40 in total

1.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

Review 2.  Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy.

Authors:  M Steven Piver
Journal:  Oncology (Williston Park)       Date:  2006-09       Impact factor: 2.990

Review 3.  Emerging roles of lipid metabolism in cancer progression.

Authors:  Cyril Corbet; Olivier Feron
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2017-07       Impact factor: 4.294

4.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

5.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

Review 6.  The multifaceted roles of fatty acid synthesis in cancer.

Authors:  Florian Röhrig; Almut Schulze
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

7.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Seiji Isonishi; Fumiaki Takahashi; Hirofumi Michimae; Eizo Kimura; Daisuke Aoki; Toshiko Jobo; Shoji Kodama; Fumitoshi Terauchi; Toru Sugiyama; Kazunori Ochiai
Journal:  Lancet Oncol       Date:  2013-08-13       Impact factor: 41.316

Review 8.  Metabolic reprogramming and cancer progression.

Authors:  Brandon Faubert; Ashley Solmonson; Ralph J DeBerardinis
Journal:  Science       Date:  2020-04-10       Impact factor: 47.728

9.  The duplicitous origin of ovarian cancer.

Authors:  Gil Mor; Ayesha Alvero
Journal:  Rambam Maimonides Med J       Date:  2013-01-30

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more
  2 in total

1.  Application of Dynamic and Static Light Scattering for Size and Shape Characterization of Small Extracellular Nanoparticles in Plasma and Ascites of Ovarian Cancer Patients.

Authors:  Ksenija Kogej; Darja Božič; Borut Kobal; Maruša Herzog; Katarina Černe
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

2.  Preoperative Serum Triglyceride to High-Density Lipoprotein Cholesterol Ratio Can Predict Prognosis in Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study.

Authors:  Junhong Li; Cong Ma; Xuhui Yuan; Xiaoyan Wang; Na Li; Ronghui Yu; Hui Liao
Journal:  Curr Oncol       Date:  2022-08-25       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.